Tim Eisen

18.5k total citations · 4 hit papers
145 papers, 12.8k citations indexed

About

Tim Eisen is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Tim Eisen has authored 145 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pulmonary and Respiratory Medicine, 85 papers in Molecular Biology and 57 papers in Cancer Research. Recurrent topics in Tim Eisen's work include Renal cell carcinoma treatment (78 papers), Renal and related cancers (48 papers) and Cancer Genomics and Diagnostics (45 papers). Tim Eisen is often cited by papers focused on Renal cell carcinoma treatment (78 papers), Renal and related cancers (48 papers) and Cancer Genomics and Diagnostics (45 papers). Tim Eisen collaborates with scholars based in United Kingdom, United States and France. Tim Eisen's co-authors include Martin Gore, Walter M. Stadler, Bernard Escudier, Brian Schwartz, Ronald M. Bukowski, Cezary Szczylik, Apurva A. Desai, Minghua Shan, Ronit Simantov and Sylvie Négrier and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Tim Eisen

143 papers receiving 12.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 3.8k citations Bernard Escudier, Tim Eisen et al. profile →
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

2006 794 citations Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology profile →
VHL, the story of a tumour suppressor gene

2014 560 citations Tim Eisen et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Tim Eisen	7.4k	7.0k	4.4k	4.1k	875	145	12.8k
Gary R. Hudes	6.1k 0.8×	6.8k 1.0×	3.5k 0.8×	3.6k 0.9×	1.2k 1.4×	102	10.7k
Viktor Grünwald	5.5k 0.7×	6.8k 1.0×	4.1k 0.9×	3.0k 0.7×	1.1k 1.2×	328	10.4k
Olivier Rixe	5.3k 0.7×	5.7k 0.8×	4.9k 1.1×	2.8k 0.7×	927 1.1×	205	11.3k
Sergio Bracarda	5.8k 0.8×	7.6k 1.1×	4.4k 1.0×	3.8k 0.9×	2.1k 2.3×	236	11.6k
M. Dror Michaelson	9.4k 1.3×	12.3k 1.8×	6.1k 1.4×	6.0k 1.5×	1.7k 1.9×	215	17.1k
Ronit Simantov	5.5k 0.7×	4.3k 0.6×	3.3k 0.8×	2.6k 0.6×	782 0.9×	88	11.2k
Bohuslav Melichar	5.4k 0.7×	6.7k 1.0×	6.3k 1.4×	3.8k 0.9×	1.5k 1.7×	503	13.2k
Brian Schwartz	7.7k 1.0×	5.8k 0.8×	5.2k 1.2×	3.3k 0.8×	1.3k 1.5×	143	14.4k
Sabino De Placido	4.4k 0.6×	4.5k 0.6×	7.8k 1.8×	3.7k 0.9×	1.2k 1.4×	381	14.0k
G. Steven Bova	7.9k 1.1×	5.2k 0.7×	2.8k 0.6×	2.9k 0.7×	1.2k 1.4×	132	12.6k

Countries citing papers authored by Tim Eisen

Since Specialization

Citations

This map shows the geographic impact of Tim Eisen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Eisen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Eisen more than expected).

Fields of papers citing papers by Tim Eisen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Eisen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Eisen. The network helps show where Tim Eisen may publish in the future.

Co-authorship network of co-authors of Tim Eisen

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Eisen. A scholar is included among the top collaborators of Tim Eisen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Eisen. Tim Eisen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oosterwijk‐Wakka, Jeannette, Loes F.M. van der Zanden, Lambertus A. Kiemeney, et al.. (2024). Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma. Neoplasia. 60. 101108–101108. 1 indexed citations

Oza, Bhavna, Tim Eisen, Eleni Frangou, et al.. (2022). External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.. Apollo (University of Cambridge). 10 indexed citations

Haas, Naomi B., Ian D. Davis, Tim Eisen, et al.. (2022). Neoadjuvant and Adjuvant Therapy for Renal Cell Carcinoma. SHILAP Revista de lepidopterología. 3(6). 464–476.

Armstrong, Andrew J., Andrew B. Nixon, Qian Yang, et al.. (2021). Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 27(12). 3317–3328. 18 indexed citations

Lawrence, Nicola Jane, Andrew Martin, Ian D. Davis, et al.. (2018). What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial. PubMed. 2(2). 123–131. 4 indexed citations

Blinman, Prunella, Andrew Martin, Shomik Sengupta, et al.. (2017). Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?. Annals of Oncology. 29(2). 370–376. 12 indexed citations

Harmon, Charles S., Samuel E. DePrimo, Robert A. Figlin, et al.. (2013). Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 73(1). 151–161. 47 indexed citations

Manola, Judith, Patrick Royston, Paul Elson, et al.. (2011). Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. Clinical Cancer Research. 17(16). 5443–5450. 148 indexed citations

Field, John K., David Baldwin, Kate Brain, et al.. (2011). CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report. Thorax. 66(8). 736–737. 24 indexed citations

10.

Escudier, Bernard, Tim Eisen, Walter M. Stadler, et al.. (2009). Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Journal of Clinical Oncology. 27(20). 3312–3318. 864 indexed citations breakdown →

11.

Eisen, Tim, Stéphane Oudard, Cezary Szczylik, et al.. (2008). Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial. JNCI Journal of the National Cancer Institute. 100(20). 1454–1463. 100 indexed citations

12.

Lorigan, Paul, Tim Eisen, & Axel Hauschild. (2008). Systemic therapy for metastatic malignant melanoma – from deeply disappointing to bright future?. Experimental Dermatology. 17(5). 383–394. 43 indexed citations

13.

Ratain, Mark J., Tim Eisen, Walter M. Stadler, et al.. (2006). Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 24(16). 2505–2512. 794 indexed citations breakdown →

14.

Rudd, Matthew, Emily L. Webb, Athena Matakidou, et al.. (2006). Variants in theGH-IGFaxis confer susceptibilityto lung cancer. Genome Research. 16(6). 693–701. 96 indexed citations

15.

O’Brien, Mary, Aleksandra Szczęsna, Petr Zatloukal, et al.. (2004). Vinorelbine alternating oral and intravenous plus carboplatinin advanced non-small-cell lung cancer: results of a multicentre phase II study. Annals of Oncology. 15(6). 921–927. 17 indexed citations

16.

Andreopoulou, Eleni, Paul J. Ross, Mary O’Brien, et al.. (2004). The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Annals of Oncology. 15(9). 1406–1412. 33 indexed citations

17.

Boer, Richard H. De, Tim Eisen, Peter Ellis, et al.. (2002). A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. Annals of Oncology. 13(6). 889–894. 5 indexed citations

18.

Smalley, Keiran S.M. & Tim Eisen. (2002). Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro‐apoptotic effects. International Journal of Cancer. 98(4). 514–522. 42 indexed citations

19.

Stebbing, Justin, Charlotte Benson, Tim Eisen, et al.. (2001). The treatment of advanced renal cell cancer with high-dose oral thalidomide. British Journal of Cancer. 85(7). 953–958. 89 indexed citations

20.

Eisen, Tim, Tamas Hickish, Ian E. Smith, John Sloane, & Suzanne A. Eccles. (1995). Small-cell lung cancer. The Lancet. 345(8960). 1285–1289. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact